Proteomics to unravel platelet-related diseases and identify novel anti-platelet drugs

Current Medicinal Chemistry

Volumn 19, Issue 27, 2012, Pages 4662-4670

  Di Michel, M ^a   Van Geet, C ^a,b   Freson, K ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Biomarkers; Diagnosis; Drug; Gel based techniques; Mass spectrometry; Molecular mechanisms; Platelet disorders; Platelets; Proteomics; Therapeutic target

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 13A; CD40 LIGAND; CILOSTAZOL; CYCLIC AMP; CYTOSKELETON PROTEIN; DASATINIB; FIBRINOGEN; GLYCOPROTEIN VI; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; RADIXIN; RGS2 PROTEIN; ROSUVASTATIN; TESTOSTERONE 17BETA DEHYDROGENASE; THROMBOSPONDIN 1; ANTITHROMBOCYTIC AGENT; PROTEOME;

ARTICLE; CEREBROVASCULAR ACCIDENT; HUMAN; NONHUMAN; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; THROMBOCYTE ACTIVATION; THROMBOCYTE DISORDER; CHEMISTRY; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; REVIEW; THROMBOCYTE;

BIOLOGICAL MARKERS; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; HUMANS; MASS SPECTROMETRY; PLATELET AGGREGATION INHIBITORS; PROTEOME; PROTEOMICS;

EID: 84875268207     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803306312     Document Type: Article

References (67)

1. Angiolillo, D.J.; Ueno, M.; Goto, S. Basic principles of platelet biology and clinical implications. Circ. J., 2010, 74(4), 597-607.
2. Ueno, M.; Kodali, M.; Tello-Montoliu, A.; Angiolillo, D.J. Role of platelets and antiplatelet therapy in cardiovascular disease. J. Atheroscler. Thromb., 2011, 18(6), 431-442.
3. Davi', G.; Patrono, C. Platelet activation and atherothrombosis. N Engl J Med 2007, 357, 2482-94.
4. Wilkins, M.R.; Sanchez, J.C.; Gooley, A.A.; Appel, R.D.; Humphery-Smith, I.; Hochstrasser, D.F.; Williams, K.L. Progress with proteome projects: Why all proteins expressed by a genome should be identified and how to do it. Biotechnol. Genet. Eng. Rev., 1996, 13, 19-50.
5. Gygi, S.P.; Rist, B.; Gerber, S.A.; Turecek, F.; Gelb, M.H.; Aebersold, R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol., 1999, 17, 994-999.
6. Casado-Vela, J.; Cebrián, A.; Gómez del Pulgar, M.T.; Sánchez-López, E.; Vilaseca, M.; Menchén, L.; Diema, C.; Sellés-Marchart, S.; Martínez-Esteso, M.J.; Yubero, N.; Bru-Martínez, R.; Lacal, J.C. Lights and shadows of proteomic technologies for the study of protein species including isoforms, splicing variants and protein post-translational modifications. Proteomics, 2011, 11(4), 590-603.
7. May, C.; Brosseron, F.; Chartowski, P.; Schumbrutzki, C.; Schoenebeck, B.; Marcus, K. Instruments and methods in proteomics. Methods Mol. Biol., 2011, 696, 3-26.
8. Gnatenko, D.V.; Perrotta, P.L.; Bahou, W.F. Proteomic approaches to dissect platelet function: Half the story. Blood, 2006, 108(13), 3983-3991.
9. Senzel, L.; Gnatenko, D.V.; Bahou, W.F. The platelet proteome. Curr. Opin. Hematol., 2009, 16(5), 329-333.
10. Zufferey, A.; Fontana, P.; Reny, J.L.; Nolli, S.; Sanchez, J.C. Platelet proteomics. Mass Spectrom. Rev., 2012, 31(2), 331-351.
11. Maurer-Spurej, E.; Kahr, W.H.; Carter, C.J.; Pittendreigh, C.; Cameron, M.; Cyr T.D. The value of proteomics for the diagnosis of a platelet-related bleeding disorder. Platelets, 2008, 19(5), 342-351.
12. Kahr, W.H.; Zheng, S.; Sheth, P.M.; Pai, M.; Cowie, A.; Bouchard, M.; Podor, T.J.; Rivard, G.E.; Hayward, C.P. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinasetype plasminogen activator. Blood, 2001, 98(2), 257-265.
13. Diamandis, M.; Paterson, A.D.; Rommens, J.M.; Veljkovic, D.K.; Blavignac, J.; Bulman, D.E.; Waye, J.S.; Derome, F.; Rivard, G.E.; Hayward, C.P. Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes. Blood, 2009, 113(7), 1543-1546.
14. Paterson, A.D.; Rommens, J.M.; Bharaj, B.; Blavignac, J.; Wong, I.; Diamandis, M.; Waye, J.S.; Rivard G.E.; Hayward, C.P. Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. Blood, 2010, 115(6), 1264-1266.
15. Maynard, D.M.; Heijnen, H.F.; Gahl, W.A.; Gunay-Aygun, M. The α-granule proteome: novel proteins in normal and ghost granules in gray platelet syndrome. J. Thromb. Haemost., 2010, 8(8), 1786-1796.
16. Gunay-Aygun, M.; Falik-Zaccai, T.C.; Vilboux, T.; Zivony-Elboum, Y.; Gumruk, F.; Cetin, M.; Khayat, M.; Boerkoel, C.F.; Kfir, N.; Huang, Y.; Maynard, D.; Dorward, H.; Berger, K.; Kleta, R.; Anikster, Y.; Arat, M.; Freiberg, A.S.; Kehrel, B.E.; Jurk, K.; Cruz, P.; Mullikin, J.C.; White, J.G.; Huizing, M.; Gahl, W.A. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules. Nat. Genet., 2011, 43(8), 732-734.
17. Kahr, W.H.; Hinckley, J.; Li, L.; Schwertz, H.; Christensen, H.; Rowley, J.W.; Pluthero, F.G.; Urban, D.; Fabbro, S.; Nixon, B.; Gadzinski, R.; Storck, M.; Wang, K.; Ryu, G.Y.; Jobe, S.M.; Schutte, B.C.; Moseley, J.; Loughran, N.B.; Parkinson, J.; Weyrich, A.S.; Di Paola, J. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat. Genet., 2011, 43(8), 738-740.
18. Di Michele, M.; Thys, C.; Waelkens, E.; Overbergh, L.; D'Hertog, W.; Mathieu, C.; De Vos, R.; Peerlinck, K.; Van Geet, C.; Freson, K. An integrated proteomics and genomics analysis to unravel a heterogeneous platelet secretion defect. J. Proteomics, 2011, 74(6), 902-913.
19. Flaumenhaft, R.; Dilks, J.R.; Rozenvayn, N.; Monahan-Earley, R.A.; Feng, D.; Dvorak, A.M. The actin cytoskeleton differentially regulates platelet alpha-granule and dense-granule secretion. Blood, 2005, 105(10), 3879-3887.
20. Pleines, I;, Eckly, A.; Elvers, M.; Hagedorn, I.; Eliautou, S.; Bender, M.; Wu, X.; Lanza, F.; Gachet, C.; Brakebusch, C.; Nieswandt, B. Multiple alterations of platelet functions dominated by increased secretion in mice lacking Cdc42 in platelets. Blood, 2010, 115(16), 3364-3373.
21. Noé, L.; Di Michele, M.; Giets, E.; Thys, C.; Wittevrongel, C.; De Vos, R.; Overbergh, L.; Waelkens, E.; Jaeken, J.; Van Geet, C.; Freson, K. Platelet Gs hypofunction and abnormal morphology resulting from a heterozygous RGS2 mutation. J. Thromb. Haemost., 2010, 8(7), 1594-1603.
22. Gu, S.; Anton, A.; Salim, S.; Blumer, K.J.; Dessauer, C.W.; Heximer, S.P. Alternative translation initiation of human regulators of G-protein signaling-2 yields a set of functionally distinct proteins. Mol. Pharmacol., 2008, 73(1), 1-11.
23. Richardson, J.L.; Shivdasani, R.A.; Boers, C.; Hartwig, J.H.; Italiano, J.E. Jr. Mechanisms of organelle transport and capture along proplatelets during platelet production. Blood, 2005, 106(13), 4066-7405.
24. Roman, D.L.; Traynor, J.R. Regulators of G protein signaling (RGS) proteins as drug targets: modulating G-protein-coupled receptor (GPCR) signal transduction. J. Med. Chem., 2011, 54(21), 7433-7440.
25. Yang, M.; Khachigian, L.M.; Hicks, C.; Chesterman, C.N.; Chong, B.H. Identification of PDGF receptors on human megakaryocytes and megakaryocytic cell lines. Thromb. Haemost., 1997, 78, 892-896.
26. den Dekker, E.; Heemskerk, J.W.; Gorter, G.; van der Vuurst, H.; Donath, J.; Kroner, C.; Mikoshiba, K.; Akkerman, J.W. Cyclic AMP raises intracellular Ca(2+) in human megakaryocytes independent of protein kinase A. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 179-186.
27. Fuhrken, P.G.; Chen, C.; Miller, W.M.; Papoutsakis, E.T. Comparative, genome-scale transcriptional analysis of CHRF-288-11 and primary human megakaryocytic cell cultures provides novel insights into lineage-specific differentiation. Exp. Hematol., 2007, 35, 476-489.
28. Di Michele, M.; Peeters, K.; Loyen, S.; Thys, C.; Waelkens, E.; Overbergh, L.; Hoylaerts, M.; Van Geet, C.; Freson, K. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Impairs the Regulation of Apoptosis in Megakaryocytes by Activating NF-B: a Proteomic Study. Mol. Cell. Proteomics, 2012, 11(1), M111.007625.
29. Freson, K.; Hashimoto, H.; Thys, C.; Wittevrongel, C.; Danloy, S.; Morita, Y.; Shintani, N.; Tomiyama, Y.; Vermylen, J.; Hoylaerts, M.F.; Baba, A.; Van Geet, C. The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation. J. Clin. Invest., 2004, 113, 905-912.
30. Freson, K.; Peeters, K.; De Vos, R.; Wittevrongel, C.; Thys, C.; Hoylaerts, M.F.; Vermylen, J.; Van Geet, C. PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications. Blood, 2008, 111, 1885-1893.
31. Peeters, K.; Stassen, J.M.; Collen, D.; Van Geet, C.; Freson, K. Emerging treatments for thrombocytopenia: increasing platelet production. Drug Discov. Today, 2008, 13(17-18), 798-806.
32. Mazharian, A.; Ghevaert, C.; Zhang, L.; Massberg, S.; Watson, S.P. Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood, 2011, 117(19), 5198-5206.
33. Veldurthy, A.; Patz, M.; Hagist, S.; Pallasch, C.P.; Wendtner, C.M.; Hallek, M.; Krause, G. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood, 2008, 112(4), 1443-1452.
34. Montero, J.C.; Seoane, S.; Ocaña, A.; Pandiella, A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin. Cancer Res., 2011, 17(17), 5546-5552.
35. Zeuner, A.; Signore, M.; Martinetti, D.; Bartuccci, M.; Peschle, C.; De Maria, R. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res., 2007, 67(10), 4767-4773.
36. Parguiña, A.F.; Grigorian-Shamajian, L.; Agra, R.M.; Teijeira-Fernández, E.; Rosa, I.; Alonso, J.; Viñuela-Roldán, J.E.; Seoane, A.; González-Juanatey, J.R.; García, A. Proteins involved in platelet signaling are differentially regulated in acute coronary syndrome: a proteomic study. PLoS One, 2010, 5(10), doi:10.1371/journal.pone.0013404.
37. Lindemann, S.; Krämer, B.; Seizer, P.; Gawaz, M. Platelets, inflammation and atherosclerosis. J. Thromb. Haemost., 2007, 5, Suppl 1203-1211.
38. López-Farré, A.J.; Zamorano-Leon, J.J.; Azcona, L.; Modrego, J.; Mateos-Cáceres, P.J.; González-Armengol, J.; Villarroel, P.; Moreno-Herrero, R.; Rodríguez-Sierra, P.; Segura, A.; Tamargo, J.; Macaya, C. Proteomic changes related to "bewildered" circulating platelets in the acute coronary syndrome. Proteomics, 2011, 11(16), 3335-3348.
39. Gebhard, S.; Steil, L.; Peters, B.; Gesell-Salazar, M.; Hammer, E.; Kuttler, B.; Clemetson, K.J.; Scharf, C.; Peters, J.; Völker, U.; Rettig, R.; Greinacher, A. Angiotensin II-dependent hypertension causes reversible changes in the platelet proteome. J. Hypertens., 2011, 29(11), 2126-2137.
40. Springer, D.L.; Miller, J.H.; Spinelli, S.L.; Pasa-Tolic, L.; Purvine, S.O.; Daly, D.S.; Zangar, R.C.; Jin, S.; Blumberg, N.; Francis, C.W.; Taubman, M.B.; Casey, A.E.; Wittlin, S.D.; Phipps, R.P. Platelet proteome changes associated with diabetes and during platelet storage for transfusion. J. Proteome Res., 2009, 8(5), 2261-2272.
41. Avila, C.; Huang, R.J.; Stevens, M.V.; Aponte, A.M.; Tripodi, D.; Kim, K.Y.; Sack, M.N. Platelet Mitochondrial Dysfunction is Evident in Type 2 Diabetes in Association with Modifications of Mitochondrial Anti-Oxidant Stress Proteins. Exp. Clin. Endocrinol. Diabetes, 2011, doi: 10.1055/s-0031-1285833.
42. Alexandru, N.; Constantin, A.; Popov, D. Carbonylation of platelet proteins occurs as consequence of oxidative stress and thrombin activation, and is stimulated by ageing and type 2 diabetes. Clin. Chem. Lab. Med., 2008, 46, 528-536.
43. Marques, M.; Sacristán, D.; Mateos-Cáceres, P.J.; Herrero, J.; Arribas, M.J.; González-Armengol, J.J.; Villegas, A.; Macaya, C.; Barrientos, A.; López-Farré, A.J. Different protein expression in normal and dysfunctional platelets from uremic patients. J. Nephrol., 2010, 23(1), 90-101.
44. Undas, A.; Brummel-Ziedins, K.E.; Mann, K.G. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood, 2007, 109(6), 2285-2292.
45. Campbell, C.L.; Steinhubl, S.R. Variability in response to aspirin: do we understand the clinical relevance? J. Thromb. Haemost., 2005, 3(4), 665-669.
46. Coppinger, J.A.; O'Connor, R.; Wynne, K.; Flanagan, M.; Sullivan, M.; Maguire, P.B.; Fitzgerald, D.J.; Cagney, G. Moderation of the platelet releasate response by aspirin. Blood, 2007, 109, 4786-4792.
47. Mateos-Cáceres, P.J.; Macaya, C.; Azcona, L.; Modrego, J.; Mahillo, E.; Bernardo, E.; Fernandez-Ortiz, A.; López-Farré, A.J. Different expression of proteins in platelets from aspirin-resistant and aspirin-sensitive patients. Thromb. Haemost., 2010, 103(1), 160-170.
48. López-Farré, A.J.; Mateos-Cáceres, P.J.; Sacristán, D.; Azcona, L.; Bernardo, E.; de Prada, T.P.; Alonso-Orgaz, S.; Fernández-Arquero, M.; Fernández-Ortiz, A.; Macaya, C. Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients: a proteomic study. J. Proteome Res., 2007, 6(7), 2481-2487.
49. Wiviott, S.D.; Antman, E.M. Clopidogrel resistance: a new chapter in a fastmoving story. Circulation, 2004, 109(25), 3064-3067.
50. Koga, Y.; Kihara, Y.; Okada, M.; Inoue, Y.; Tochizawa, S.; Toga, K.; Tachibana, K.; Kimura, Y.; Nishi, T., Hidaka, H. 2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and antihyperplastic activities. Bioorg. Med. Chem. Lett., 1998, 8, 1471-1476.
51. Yoshida, H.; Okamura, Y.; Watanabe, N.; Ikeda, Y.; Handa, M. Sheardependent suppression of platelet thrombus formation by phosphodiesterase 3 inhibition requires low levels of concomitant Gs-coupled receptor stimulation. Thromb. Haemost., 2011, 105(3), 487-495.
52. Ansara, A.J.; Shiltz, D.L.; Slavens, J.B. Use of Cilostazol for Secondary Stroke Prevention: An Old Dog with New Tricks? (March). Ann. Pharmacother., 2012, Epub ahead of print.
53. Shinohara, Y.; Katayama, Y.; Uchiyama, S.; Yamaguchi, T.; Handa, S.; Matsuoka, K.; Ohashi, Y.; Tanahashi, N.; Yamamoto, H.; Genka, C.; Kitagawa, Y.; Kusuoka, H.; Nishimaru, K.; Tsushima, M.; Koretsune, Y.; Sawada, T.; Hamada, C.; CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised noninferiority trial. Lancet Neurol., 2010, 9(10), 959-968.
54. Hashimoto, K.; Ishima, T. Neurite outgrowth mediated by translation elongation factor eEF1A1: a target for antiplatelet agent cilostazol. PLoS One, 2011, 6(3), e17431.
55. Schulz, C.; Leuschen, N.V.; Fröhlich, T.; Lorenz, M.; Pfeiler, S.; Gleissner, C.A.; Kremmer, E.; Kessler, M.; Khandoga, A.G.; Engelmann, B.; Ley, K.; Massberg, S.; Arnold, G.J. Identification of novel downstream targets of platelet glycoprotein VI activation by differential proteome analysis: implications for thrombus formation. Blood, 2010, 115, 4102-4110.
56. Reinhardt, C.; von Brühl, M.L.; Manukyan, D.; Grahl, L.; Lorenz, M.; Altmann, B.; Dlugai, S.; Hess, S.; Konrad, I.; Orschiedt, L.; Mackman, N.; Ruddock, L.; Massberg, S.; Engelmann, B. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J. Clin. Invest., 2008, 118(3), 1110-1122.
57. Grüner, S.; Prostredna, M.; Aktas, B.; Moers, A.; Schulte, V.; Krieg, T.; Offermanns, S.; Eckes, B.; Nieswandt, B. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy. Circulation, 2004, 110, 2946-2951.
58. Senis, Y.A.; Antrobus, R.; Severin, S.; Parguina, A.F.; Rosa, I.; Zitzmann, N.; Watson, S.P.; Garcia, A. Proteomic analysis of integrin alphaIIbbeta3 outside-in signaling reveals Src-kinase-independent phosphorylation of Dok-1 and Dok-3 leading to SHIP-1 interactions. J. Thromb. Haemost. 2009, 7, 1718-1726.
59. Newland, S.A.; Macaulay, I.C.; Floto, A.R.; de Vet, E.C.; Ouwehand, W.H.; Watkins, N.A.; Lyons, P.A.; Campbell, D.R. The novel inhibitory receptor G6B is expressed on the surface of platelets and attenuates platelet function in vitro. Blood, 2007, 109(11), 4806-4809.
60. Mori, J.; Pearce, A.C.; Spalton, J.C.; Grygielska, B.; Eble, J.A.; Tomlinson, M.G.; Senis, Y.A.; Watson, S.P. G6b-B inhibits constitutive and agonistinduced signaling by glycoprotein VI and CLEC-2. J. Biol. Chem., 2008, 283(51), 35419-35427.
61. Tucker, K.L.; Kaiser, W.J.; Bergeron, A.L.; Hu, H.; Dong, J.F.; Tan, T.H.; Gibbins, J.M. Proteomic analysis of resting and thrombin-stimulated platelets reveals the translocation and functional relevance of HIP-55 in platelets. Proteomics, 2009, 9(18), 4340-4354.
62. Baig, A.; Bao, X.; Haslam, R.J. Proteomic identification of pleckstrin associated proteins in platelets: possible interactions with actin. Proteomics 2009, 9(17), 4254-4258.
63. Lian, L.; Wang, Y.; Flick, M.; Choi, J.; Scott, E.W.; Degen, J.; Lemmon, M.A.; Abrams, C.S. Loss of pleckstrin defines a novel pathway for PKCmediated exocytosis. Blood, 2009, 113, 3577-3584.
64. Goodall, A.H.; Burns, P.; Salles, I.; Macaulay, I.C.; Jones, C.I.; Ardissino, D.; de Bono, B.; Bray, S.L.; Deckmyn, H.; Dudbridge, F.; Fitzgerald, D.J.; Garner, S.F.; Gusnanto, A.; Koch, K.; Langford, C.; O'Connor, M.N.; Rice, C.M.; Stemple, D.; Stephens, J.; Trip, M.D.; Zwaginga, J.J.; Samani, N.J.; Watkins, N.A.; Maguire, P.B.; Ouwehand, W.H; Bloodomics Consortium. Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. Blood, 2010, 116(22), 4646-4656.
65. Coppinger, J.A.; Cagney, G.; Toomey, S.; Kislinger, T.; Belton, O.; McRedmond, J.P.; Cahill, D.J.; Emili, A.; Fitzgerald, D.J.; Maguire, P.B. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood, 2004, 103, 2096-2104.
66. Schonbeck, U.; Sukhova, G.K.; Shimizu, K.; Mach, F.; Libby, P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc. Natl. Acad. Sci. U S A, 2000, 97, 7458-7463.
67. Molins, B.; Peña, E.; Padro, T.; Casani, L.; Mendieta, C.; Badimon, L. Glucose-regulated protein 78 and platelet deposition: effect of rosuvastatin. Arterioscler. Thromb. Vasc. Biol., 2010, 30(6), 1246-1252.